Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse?

FASEB Journal

Volumn 18, Issue 6, 2004, Pages 637-647

  Sidhu, Anita ^a,c   Wersinger, Christophe ^a   Vernier, Philippe ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNRS   (France)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Dopamine transporter; Lewy bodies; MPTP; Neurodegeneration; Parkinson's disease; Synucleopathies

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE;

CELL LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; HUMAN; NERVE DEGENERATION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STORAGE; SYNAPSE; SYNAPSE VESICLE;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; SYNAPSES; SYNAPTIC VESICLES; SYNUCLEINS; TYROSINE 3-MONOOXYGENASE;

EID: 1842454976     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.03-1112rev     Document Type: Review

References (146)

1. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature (London) 388, 839-840
2. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., and Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208
3. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473
4. Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., and Takahashi, H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239, 45-48
5. Irizarry, M. C., Growdon, W., Gomez-Isla, T., Newell, K., George, J. M., Clayton, D. F., and Hyman, B. T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334-337
6. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M. Y., Trojanowski, J. Q., and Iwatsubo, Y. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884
7. Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L., and Masliah, E. (1998) Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol. 152, 367-372
8. Trojanowski, J. Q., and Lee, V. M. Y. (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55, 151-152
9. Tu, P. H., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., and Lee, V. M. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415-422
10. Gai, W. P., Power, J. H. T., Blumberg, P. C., and Blessing, W. W. (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352, 547-548
11. Lippa, C. F., Schmidt, M. L., Lee, V. M., and Trojanowski, J. Q. (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357
12. Goedert, M., and Spillantini, M. G. (1998) Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol. Psychiatry 3, 462-465
13. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
14. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
15. Chan, P., Jiang, X., Forno, L. S., DiMonte, D. A., Tanner, C. M., and Langston, J. W. (1998) Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology 50, 1136-1137
16. Wakabayashi, K., Engelender, S., Yoshimoto, M., Tsuji, S., Ross, C. A., and Takahashi, H. (2000) Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47, 521-523
17. Scott, W. K., Yamaoka, L. H., Stajich, J. M., Scott, B. L., Vance, J. M., Roses, A. D., Pericak-Vance, M. A., Watts, R. L., Nance, M., Hubble, J., et al. (1999) The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 2, 191-192
18. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449
19. Eliezer, D., Kutluay, E., Bussell, R., Jr., and Browne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073
20. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349
21. Lee, H.J., and Lee, S.J. (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976-48983
22. Goedert, M., Spillantini, M. G., and Davies, S. W. (1998) Filamentous nerve cell inclusions in neurodegenerative diseases. Curr. Opin. Neurobiol. 8, 619-632
23. El-Agnaf, O. M., Jakes, R., Curran, M. D., and Wallace, A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70
24. Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., and Masliah, E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10, 717-721
25. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843-9846
26. Clayton, D. F., and George, J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249-254
27. Lavedan, C. (1998) The synuclein family. Genome Res. 8, 871-880
28. Lucking, C. B., and Brice, A. (2000) Alpha-synuclein and Parkinson's disease. Cell. Mol. Life Sci. 57, 1894-1908
29. Kahle, P. J., Neumann, M., Ozman, L., and Haass, C. (2000) Physiology and pathophysiology of α-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. N.Y. Acad. Sci. 920, 33-41
30. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576
31. El-Agnaf, O. M., and Irvine, G. B. (2000) Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130, 300-309
32. Mouradian, M. M. (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58, 179-185
33. Mori, F., Tanji, K., Yoshimoto, M., Takahashi, H., and Wakabayashi, K. (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp. Neurol. 176, 98-104
34. Maker, H. S., Weiss, C., Silides, D. J., and Cohen, G. (1981) Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36, 589-593
35. Youdim, M. B. (2003) What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease? J. Neural Transm. Suppl. 65, 73-88
36. Graham, D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol. Pharmacol. 14, 633-643
37. Lotharius, J., and Brundin, P. (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 11, 2395-2407
38. Lotharius, J., and Brundin, P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3, 932-942
39. Goedert, M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501
40. George, J. M. (2002) The synucleins. Genome Biol. 3, 1-6
41. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1994) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11282-11286
42. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32
43. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815
44. Petersen, K., Olesen, O. F., and Mikkelsen, J. D. (1999) Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651-659
45. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475
46. Clayton, D. F., and George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129
47. Irizarry, M. C., Kim, T. W., McNamara, M., Tanzi, R. E., George, J. M., Clayton, D. F., and Hyman, B. T. (1996) Characterisation of the precursor of the non-A β component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889-895
48. Kahle, P. J., Neumann, M., Ozman, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A., et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373
49. Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., and Selkoe, D.J. (2001) Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA 98, 9110-9115
50. Galvin, J. E., Schuck, T. M., Lee, V. M., and Trojanowski, J. Q. (2001) Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp. Neurol. 168, 347-355
51. Jakowec, M. W., Donaldson, D. M., Barba, J. and Petzinger, G. M. (2001) Postnatal expression of alpha-synuclein protein in rodent substantia nigra and striatum. Dev. Neurosci. 23, 91-99
52. Li, J. Y., Henning Jensen, P., and Dahlstrom, A. (2002) Differential localization of alpha, beta- and gamma-synucleins in the rat CNS. Neuroscience 113, 463-478
53. Mori, F., Tanji, K., Yoshimoto, M., Takahashi, H., and Wakabayashi, K. (2002) Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 941, 118-126
54. Quilty, M. C., Gai, W. P., Pountney, D. L., West, A. K., and Vickers, J. C. (2003) Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp. Neurol. 182, 195-207
55. Uversky, V. N. (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211-234
56. Chandra, S., Chen, X., Rizo, J., Jahn, R., and Sudhof, T. C. (2003) A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. 278, 15313-15318
57. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269
58. Giasson, B. I., Murray, I. V., Trojanowski, J. Q., and Lee, V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386
59. Bodles, A. M., Guthrie, D.J., Greer, B., and Irvine, G. B. (2001) Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78, 384-395
60. El-Agnaf, O. M., and Irvine, G. B. (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30, 559-565
61. Du, H. N., Tang, L., Luo, X. Y., Li, H. T., Hu, J., Zhou, J. W., and Hu, H. Y. (2003) A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 42, 8870-8878
62. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., and Wolozin, B. (1999) Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791
63. Kim, T. D., Paik, S. R., Yang, C. H., and Kim, J. (2000) Structural changes in alpha-synuclein affect its chaperone-like activity in vitro. Protein Sci. 9, 2489-2496
64. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal pathway. Neuron 25, 239-252
65. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807
66. Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., and Brundin, P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894
67. Jenco, J. M., Rawlingson, A., Daniels, B., and Morris, A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α and β-synucleins. Biochemistry 37, 4901-4909
68. Ahn, B. H., Rhim, H., Kim, S. Y., Sung, Y. M., Lee, M. Y., Choi, J. Y., Wolozin, B., Chang, J. S., Lee, Y. H., Kwon, T. K., Chung, K. C., Yoon, S. H., Hahn, S.J., Kim, M. S., Jo, Y. H., and Min do, S. (2002) α-synuclein interacts with phospholipase D isozymes and inhibits pervanadate induced phospholipase D activation in human embryonic kidney 293 cells. J. Biol. Chem. 277, 12334-12342
69. Liscovitch, M., Czarny, M., Fiucci, G., and Tang, X. (2000) Phospholipase D: molecular and cell biology of a novel gene family. Biochem. J. 345, 401-415
70. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397
71. Jensen, P. H., Hojrup, P., Hager, H., Nielsen, M. S., Jacobsen, L., Olesen, O. F., Gliemann, J., and Jakes, R. (1999) Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalysed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25481-25489
72. Pronin, A. N., Morris, A. J., Surguchov, A., and Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522
73. Ellis, C. E., Schwartzberg, P. L., Grider, T. L., Fink, D. W., and Nussbaum, R. L. (2001) alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276, 3879-3884
74. Nakamura, T., Yamashita, H., Nagano, Y., Takahashi, T., Avraham, S., Avraham, H., Matsumoto, M., and Nakamura, S. (2002) Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. FEBS Lett. 521, 190-194
75. Schmidt, A., Wolde, M., Thiele, C., Fest, W., Kratzin, H., Podtelejnikov, A. V., Witke, W., Huttner, W. B., and Soling, H. D. (1999) Endophilin 1 mediates synaptic vesicle formation by transfer arachidonate to lysophosphatidic acid. Nature (London) 401, 133-141
76. Heuser, J. E., and Reese, T. S. (1973) Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction. J. Cell Biol. 57, 315-344
77. Martinez, J., Moeller, I., Erdjument-Bromage, H., Tempst, P., and Lauring, B. (2003) Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17379-17387
78. Lee, D., Lee, S. Y., Lee, E. N., Chang, C. S., and Paik, S. R. (2002) Alpha-synuclein exhibits competitive interaction between calmodulin and synthetic membranes. J. Neurochem. 82, 1007-1017
79. Petersen, K., Olesen, O. F., and Mikkelsen, J. D. (1999) Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651-659
80. Stephan, A., Davis, S., Salin, H., Dumas, S., Mallet, J., and Laroche, S. (2002) Age-dependent differential regulation of genes encoding APP and alpha-synuclein in hippocampal synaptic plasticity. Hippocampus 12, 55-62
81. Eells, J. B. (2003) The control of dopamine neuron development, function and survival: insights from transgenic mice and the relevance to human disease. Curr. Med. Chem. 10, 857-870
82. Kholodilov, N. G., Neystat, M., Oo, T. F., Lo, S. E., Larsen, K. E., Sulzer, D., and Burke, R. E. (1999) Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73, 2586-2599
83. Kholodilov, N. G., Oo, T. F., and Burke, R. E. (1999) Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. Neurosci. Lett. 275, 105-108
84. Quilty, M. C., Gai, W. P., Pountney, D. L., West, A. K., and Vickers, J. C. (2003) Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp. Neurol. 182, 195-207
85. Lee, M. H., Hyun, D. H., Halliwell, B., and Jenner, P. (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009
86. Alves da Costa, C., Ancolio, K., and Checler, F. (2000) Wild-type but not Parkinson's disease-related ala-53→Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069
87. Hashimoto, M., Hsu, L. J., Rockenstein, E., Takenouchi, T., Mallory, M., and Masliah, E. (2002) Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277, 11465-11472
88. Seo, J. H., Rah, J. C., Choi, S. H., Shin, J. K., Min, K., Kim, H. S., Park, C. H., Kim, S., Kim, E. M., Lee, S. H., et al. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and P13/Akt kinase pathway. FASEB J. 16, 1826-1828
89. Jensen, P. J., Alter, B. J., and O'Malley, K. L. (2003) Alpha-synuclein protects naïve but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity. J. Neurochem. 86, 196-209
90. Manning-Bog, A. B., McCormack, A. L., Purisai, M. G., Bolin, L. M., and Di Monte, D. A. (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095-3099
91. Payton, J. E., Perrin, R. J., Clayton, D. F., and George, J. M. (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res. Mol. Brain Res. 95, 138-145
92. Alim, M. A., Hossain, M. S., Arima, K., Takeda, K., Izumiyama, Y., Nakamura, M., Kaji, H., Shinoda, T., Hisanaga, S., and Ueda, K. (2002) Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277, 2112-2117
93. Jensen, P. H., Islam, K., Kenney, J., Nielsen, M. S., Power, J., and Gai, W. P. (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J. Biol. Chem. 275, 21500-21507
94. D'Andrea, M. R., Ilyin, S., and Plata-Salaman, C. R. (2001) Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues. Neurosci. Lett. 306, 137-142
95. Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F., et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110-114
96. Kawamata, H., McLean, P. J., Sharma, N., and Hyman, B. T. (2001) Interaction of α-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. J. Neurochem. 77, 929-934
97. Sharma, N., Hewett, J., Ozelius, L.J., Ramesh, V., McLean, P.J., Breakefield, X. O., and Hyman, B. T. (2001) A close association of torsin A and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am. J. Pathol. 159, 339-344
98. Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., and Greene, L. A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560
99. Kumer, S. C., and Vrana, K. E. (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462
100. Xu, J., Kao, S. Y., Lee, F.J., Song, W., Jin, L. W., and Yankner, B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8, 600-606
101. 2+ calmodulin-dependent protein kinase 11. FEBS Lett. 219, 79-82
102. Ichimura, T., Isobe, T., Okuyama, T., Takahashi, N., Araki, K., Kuwano, R., and Takahashi, Y. (1988) Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl. Acad. Sci. USA 85, 7084-7088
103. Toska, K., Kleppe, R., Armstrong, C. G., Morrice, N. A., Cohen, P., and Haavik, J. (2002) Regulation of tyrosine hydroxylase by stress-activated protein kinases. J. Neurochem. 83, 775-783
104. Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., and Zigmond, M.J. (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099
105. Dhillon, A. S., Meikle, S., Peyssonnaux, C., Grindlay, J., Kaiser, C., Steen, H., Shaw, P. E., Mischak, H., Eychene, A., and Kolch, W. (2003) A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol. Cell. Biol. 23, 1983-1993
106. Dai, J. G., and Murakami, K. (2003) Constitutively and autonomously active protein kinase C associated with 14-3-3 zeta in the rodent brain. J. Neurochem. 84, 23-34
107. Iwata, A., Maruyama, M., Kanazawa, I., and Nukina, N. (2001) α-synuclein affects the MAPK pathway and accelerates cell death. J. Biol. Chem. 276, 45320-45329
108. Iwata, A., Miura, S., Kanazawa, I., Sawada, M., and Nukina, N. (2001) α-synuclein forms a complex with transcription factor Elk-1. J. Neurochem. 77, 239-252
109. Lee, C. S., Samii, A., Sossi, V., Ruth, T.J., Schulzer, M., Holden, J. E., Wudel, J. Pal, P. K., de la Fuente-Fernandez, R., Calne, D. B., et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47, 493-503
110. Parsons, S. M. (2000) Transport mechanisms in acetylcholine and monoamine storage. FASEB J. 14, 2423-2434
111. Eiden, L. E. (2000) The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J. 14, 2396-2400
112. Weihe, E., and Eiden, L. E. (2000) Chemical neuroanatomy of the vesicular amine transporters. FASEB J. 14, 2435-2449
113. Gainetdinov, R. R., Fumagalli, F., Wang, Y. M., Jones, S. R., Levey, A. I., Miller, G. W., and Caron, M. G. (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70, 1973-1978
114. Uhl, G. R., Li, S., Takahashi, N., Itokawa, K., Lin, Z., Hazama, M., and Sora, I. (2000) The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 14, 2459-2465
115. Goldberg, M. S., and Lansbury, P. T., Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119
116. Volles, M.J., and Lansbury, P. T., Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602
117. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (London) 418, 291
118. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T., Jr. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1092
119. Zhu, M., Li, J., and Fink, A. L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability and fibril formation. J. Biol. Chem. 278, 40186-40197
120. Chen, N., and Reith, M. E. (2000) Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405, 329-339
121. Gainetdinov, R. R., and Caron, M. G. (2003) Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43, 261-284
122. - neurotransmitter transporters. J. Neurochem. 71, 1785-1803
123. Torres, G. E., Gainetdinov, R. R., and Caron, M. G. (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4, 13-25
124. --dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther. 92, 21-55
125. Gainetdinov, R. R., Fumagalli, F., Jones, S. R., and Caron, M. G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325
126. Takahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostic, V., Jackson-Lewis, V., Przedborski, S., and Uhl, G. R. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94, 9938-9943
127. Pristupa, Z. B., McConkey, F., Liu, F., Man, H. Y., Lee, F. J., Wang, Y. T., and Niznik, H. B. (1998) Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30, 79-87
128. Melikian, H. E., and Buckley, K. M. (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19, 7699-7710
129. Daniels, G. M., and Amara, S. G. (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation, in response to phorbol esters. J. Biol. Chem. 274, 35794-35801
130. Moron, J. A., Zakharova, I., Ferrer, J. V., Merrill, G. A., Hope, B., Lafer, E. M., Lin, Z. C., Wang, J. B., Javitch, J. A., Galli, A., et al. (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23, 8480-8488
131. Wersinger, C., and Sidhu, A. (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340, 189-192
132. Wersinger, C., Prou, D., Vernier, P., and Sidhu, A. (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151-2153
133. Wersinger, C., Prou, D., Vernier, P., Niznik, H. B., and Sidhu, A. (2003) Mutations in the lipid-binding domain of α-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol. Cell. Neurosci. 24, 91-105
134. Lee, F. J., Liu, F., Pristupa, Z. B., and Niznik, H. B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926
135. Wersinger, C., Vernier, P., and Sidhu, A. (2004) Bidirectional trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Biochemistry In press
136. Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521-533
137. Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., and Federoff, H. J. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 35-48
138. Feany, M. B., and Bender, W. W. (2000) A Drosophila model of Parkinson's disease. Nature (London) 404, 394-398
139. Giasson, B. I., and Lee, V. M. (2003) Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8
140. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269
141. Yang, Y., Nishimura, I., Imai, Y., Takahashi, R., and Lu, B. (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37, 911-924
142. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature (London) 395, 451-452
143. Ciliax, B. J., Drash, G. W., Staley, J. K., Haber, S., Mobley, C. J., Miller, G. W., Mufson, E.J., Mash, D. C., and Levey, A. I. (1999) Immunocytochemical localization of the dopamine transporter in human brain. J. Comp. Neurol. 409, 38-56
144. Kakimura, J., Kitamura, Y., Takata, K., Kohno, Y., Nomura, Y., and Taniguchi, T. (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59-67
145. Kanda, S., Bishop, J. F., Eglitis, M. A., Yang, Y., and Mouradian, M. M. (2000) Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97, 279-284
146. Dauer, W., Kholodilov, N., Vila, M., Trillat, A. C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) Resistance of alpha-synuclein nul mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99, 14524-14529